Showing 6371-6380 of 8892 results for "".
- Foamix Establishes U.S. Subsidiary and Strengthens Executive Management With Appointment of Senior U.S. Leadership Teamhttps://practicaldermatology.com/news/20140611-foamix_establishes_us_subsidiary_and_strengthens_executive_management_with_appointment_of_senior_us_leadership_team/2459209/Foamix Pharmaceuticals, a clinical-stage, specialty pharmaceutical company focused on the development, patenting and commercialization of proprietary topical foams to address unmet needs in dermatology, today announced the establishment of its U.S. Subsidiary and appointment of five industry veteran
- New Data Demonstrate Efficacy of ClarityMD OTC Acne Systemhttps://practicaldermatology.com/news/20140611-new_data_demonstrate_efficacy_of_claritymd_otc_acne_system/2459210/Newly published data show the efficacy of Envy Medical's ClarityMD acne system. Results of a clinical study designed by Envy, demonstrate that ClarityMD is effective in quickly and gently clearing both inflammatory and non-inflammatory acn
- San Francisco Dermatologist Elected to AMA Board of Trusteeshttps://practicaldermatology.com/news/20140611-san_francisco_dermatologist_elected_to_ama_board_of_trustees/2459211/Jack Resneck Jr., MD, a dermatologist from San Francisco, CA, was elected to the American Medical Association (AMA) Board of Trustees. "I am honored to be elected to the AMA Board of Trustees," said Resneck. "Our AMA has an influential role to play in c
- Allergan Again Unanimously Rejects Valeant's Revised Unsolicited Proposalhttps://practicaldermatology.com/news/20140610-allergan_again_unanimously_rejects_valeants_revised_unsolicited_proposal/2459212/Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced Tuesday that its board of directors, after consulting with its independent financial and legal advisors
- Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosishttps://practicaldermatology.com/news/20140609-valeant_pharmaceuticals_announces_fda_approval_of_jublia_for_the_treatment_of_onychomycosis/2459213/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole
- AAD Announces Donation of Melanoma Exposed Program from Bristol-Myers Squibbhttps://practicaldermatology.com/news/20140609-aad_announces_donation_of_melanoma_exposed_program_from_bristol-myers_squibb/2459214/Bristol-Myers Squibb donated its Melanoma Exposed™ program to the American Academy of Dermatology (AAD). The donation, provided through a charitable grant, will be used to increase public awareness of skin cancer—including melanoma, the deadliest form of skin cancer—and expand t
- Allergan: Business As Usual Following New Valeant Offerhttps://practicaldermatology.com/news/20140606-allergan_business_as_usual_following_new_valeant_offer/2459215/At Allergan, executives say it is business as usual, even as the board reviews a hefty new offer from Valeant. Valeant last Friday increased its offer to Allergan by $14 per share, “subject to prompt good-faith discussions on a merger agreement.” The new bid values Allergan at about $180 a share and
- Cosmetic Surgery Forum Unveils 2014 Agendahttps://practicaldermatology.com/news/20140606-cosmetic_surgery_forum_unveils_2014_agenda/2459216/The agenda for the 2014 Cosmetic Surgery Forum was recently unveiled. The meeting will take place from December 3 through December 6 at the Palazzo Casino and Resort in Las Vegas, NV. Under course director Joel Schlessinger, MD, this year's meeting will include sessions on cosmetic treatments for me
- Allergan Comments on Pershing Square's and Valeant's Attempt to Remove a Majority of the Members of the Allergan Board of Directorshttps://practicaldermatology.com/news/20140602-allergan_comments_on_pershing_squares_and_valeants_attempt_to_remove_a_majority_of_the_members_of_the_allergan_board_of_directors/2459220/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today issued the following statement regarding the filing by Pershing Square Capital Management, L.P. ("Pershing Square") of preliminary proxy materials with the Securities and Exchange Commission ("SEC") in order to solicit proxies to call a
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced